Compare Stocks: SUPN, LNTH, AMRX, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$20.21 -1.1%	$19.17	$10.92 ▼ $21.68	$6.45B	1.22	2.41 million shs	6.44 million shs
BLTE Belite Bio	$152.17 -1.0%	$161.32	$102.00 ▼ $200.00	$6.13B	-1.23	189,261 shs	149,875 shs
LNTH Lantheus	$100.80 +0.5%	$100.27	$50.15 ▼ $111.86	$6.58B	-0.06	1.08 million shs	748,574 shs
SUPN Supernus Pharmaceuticals	$28.15 -32.8%	$42.42	$27.97 ▼ $59.68	$1.64B	0.55	815,195 shs	7.83 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-4.97%	-2.76%	+0.69%	+10.61%	+89.08%
BLTE Belite Bio	-0.69%	+7.20%	-3.69%	-2.29%	+45.11%
LNTH Lantheus	-0.15%	+0.39%	+0.35%	-0.79%	+73.88%
SUPN Supernus Pharmaceuticals	0.00%	+2.82%	-1.09%	-3.08%	-23.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$20.21 -1.1%	$19.17	$10.92 ▼ $21.68	$6.45B	1.22	2.41 million shs	6.44 million shs
BLTE Belite Bio	$152.17 -1.0%	$161.32	$102.00 ▼ $200.00	$6.13B	-1.23	189,261 shs	149,875 shs
LNTH Lantheus	$100.80 +0.5%	$100.27	$50.15 ▼ $111.86	$6.58B	-0.06	1.08 million shs	748,574 shs
SUPN Supernus Pharmaceuticals	$28.15 -32.8%	$42.42	$27.97 ▼ $59.68	$1.64B	0.55	815,195 shs	7.83 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	-4.97%	-2.76%	+0.69%	+10.61%	+89.08%
BLTE Belite Bio	-0.69%	+7.20%	-3.69%	-2.29%	+45.11%
LNTH Lantheus	-0.15%	+0.39%	+0.35%	-0.79%	+73.88%
SUPN Supernus Pharmaceuticals	0.00%	+2.82%	-1.09%	-3.08%	-23.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.89	Moderate Buy	$22.86	13.10% Upside
BLTE Belite Bio	2.64	Moderate Buy	$227.40	49.44% Upside
LNTH Lantheus	2.21	Hold	$107.44	6.59% Upside
SUPN Supernus Pharmaceuticals	1.75	Reduce	$62.33	121.43% Upside

Current Analyst Ratings Breakdown

Latest SUPN, LNTH, AMRX, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	SUPN Supernus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D-)
10/29/2026	AMRX Amneal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$24.00
10/26/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/22/2026	AMRX Amneal Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$22.00 ➝ $24.00
10/15/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C+) ➝ Hold (C)
10/15/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$245.00
10/13/2026	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$115.00 ➝ $109.00
10/8/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/6/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/5/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/2/2026	BLTE Belite Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.14	$1.49 per share	13.54	($0.23) per share	-87.87
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
LNTH Lantheus	$1.54B	4.27	$6.43 per share	15.68	$16.43 per share	6.14
SUPN Supernus Pharmaceuticals	$718.95M	2.28	$2.59 per share	10.88	$18.52 per share	1.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	41.24	18.21	2.46	5.05%	-584.46%	7.78%	N/A
BLTE Belite Bio	-$77.61M	-$2.73	N/A	167.22	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.35	17.97	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$0.77	N/A	7.65	1.21	-13.23%	11.13%	8.10%	N/A

Latest SUPN, LNTH, AMRX, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	BLTE Belite Bio	-$0.7863	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	LNTH Lantheus	$1.24	N/A	N/A	N/A	$360.07 million	N/A
11/3/2026	Q3 2026	AMRX Amneal Pharmaceuticals	$0.23	$0.26	+$0.03	-$0.06	N/A	$862.68 million
10/29/2026	Q3 2026	SUPN Supernus Pharmaceuticals	$0.49	$0.35	-$0.14	$0.35	$217.56 million	$208.60 million
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest SUPN, LNTH, AMRX, and BLTE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/16/2026	SUPN Supernus Pharmaceuticals	special	$8.13			10/30/2026	11/6/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Optionable
LNTH Lantheus	1,193	65.30 million	64.19 million	Optionable
SUPN Supernus Pharmaceuticals	778	58.22 million	53.29 million	Optionable

SUPN, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year Low - Here's Why

November 3 at 9:59 AM | marketbeat.com

Supernus Completes Merger With Indivior; Creates CNS-Focused Biopharma

November 3 at 7:18 AM | rttnews.com

Profund Advisors LLC Purchases 30,456 Shares of Supernus Pharmaceuticals, Inc. $SUPN

November 3 at 5:28 AM | marketbeat.com

Indivior Pharmaceuticals, Inc. completed the acquisition of Supernus Pharmaceuticals, Inc. from group of shareholders in a merger of equals transaction.

November 3 at 2:17 AM | marketscreener.comM

Supernus Pharmaceuticals Completes Merger, Begins Nasdaq Delisting Process

November 2 at 11:51 AM | tipranks.com

Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals

November 2 at 10:11 AM | tipranks.com

Indivior Completes Merger with Supernus, Expanding CNS Portfolio

November 2 at 10:11 AM | tipranks.com

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

November 2 at 9:18 AM | globenewswire.com

Comparing Supernus Pharmaceuticals (NASDAQ:SUPN) & Assembly Biosciences (NASDAQ:ASMB)

November 2 at 3:23 AM | americanbankingnews.com

SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger

October 30, 2026 | msn.com

Supernus Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2026

October 30, 2026 | marketscreener.comM

Supernus (SUPN) Q3 2026 Earnings Call Transcript

October 30, 2026 | finance.yahoo.com

Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

October 30, 2026 | marketscreener.comM

Supernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS

October 29, 2026 | marketbeat.com

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

October 29, 2026 | seekingalpha.com

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

October 29, 2026 | zacks.com

Supernus Pharmaceuticals Q3 Earnings Call Highlights

October 29, 2026 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic

October 29, 2026 | finance.yahoo.com

Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript

October 29, 2026 | benzinga.com

Supernus Announces Third Quarter 2026 Financial Results

October 29, 2026 | globenewswire.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Here's Why

October 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$20.21 -0.23 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$20.08 -0.13 (-0.64%)

As of 06:36 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio NASDAQ:BLTE

$152.17 -1.50 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$152.34 +0.18 (+0.12%)

As of 05:24 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$100.80 +0.49 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$100.83 +0.03 (+0.03%)

As of 04:23 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Supernus Pharmaceuticals NASDAQ:SUPN

$28.15 -13.77 (-32.85%)

As of 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SUPN, LNTH, AMRX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SUPN, LNTH, AMRX, and BLTE Earnings

Compare Dividends

Latest SUPN, LNTH, AMRX, and BLTE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SUPN, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SUPN, LNTH, AMRX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SUPN, LNTH, AMRX, and BLTE Earnings

Compare Dividends

Latest SUPN, LNTH, AMRX, and BLTE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SUPN, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools